DDIT3 and diffuse large B-cell lymphoma: In DLBCL, the OLYMPIA-3 trial (NCT06091865) is evaluating odronextamab with CHOP compared to R-CHOP in previously untreated patients, and OLYMPIA-4 includes R/R DLBCL.